Results 71 to 80 of about 8,911,089 (208)

Baseline characteristics in patients with or without (A) major adverse cardiovascular events (MACE) and major coronary events (MCE), or (B) cardiovascular (CV) death or hospitalization for heart failure (HF hosp) or myocardial infarction (MI) in the STABILITY validation study.

, 2023
Baseline characteristics in patients with or without (A) major adverse cardiovascular events (MACE) and major coronary events (MCE), or (B) cardiovascular (CV) death or hospitalization for heart failure (HF hosp) or myocardial infarction (MI) in the ...
Niclas Eriksson (265808), Andrea Ballagi (17389614), Martin Lundberg (584387), Mikael Åberg (8051549), Ralph A. H. Stewart (9982175), Agneta Siegbahn (203316), Claes Held (48065), Lars Wallentin (68990), Erika Assarsson (58597), Harvey D. White (4284952)   +9 more
core   +1 more source

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events

JAMA Dermatology
Importance The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs).
Raby, Maxime, Balusson, Frederic, Oger, Emmanuel, Gundelwein, Marion, Dupuy, Alain, Poizeau, Florence   +5 more
openaire   +4 more sources

Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials

Frontiers in Medicine
IntroductionThe aims of this study is to analyze the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis treated with secukinumab and ixekizumab.MethodologyWe systematically identified randomized controlled trials (RCTs) that ...
Yonghong Zhang, Zhiya Yang, Jinyan Gong, Dongmei Shi, Dongmei Shi   +4 more
doaj   +1 more source

Hazard ratios (95% confidence intervals) for 10-year major adverse cardiovascular events and all-cause mortality for predicted statin response and cardiovascular risk groups.

, 2021
Hazard ratios (95% confidence intervals) for 10-year major adverse cardiovascular events and all-cause mortality for predicted statin response and cardiovascular risk groups.
Wallis C. Y. Lau (3161145), Barbara Iyen (11785401), Esther W. Chan (8190144), Joe Kai (508035), Kenneth KC Man (11785398), Chung Wah Siu (11785407), Ralph Kwame Akyea (11785395), Stephen Franklin Weng (11785392), Nadeem Qureshi (508036), Joseph Edgar Blais (11785404), Ian C. K. Wong (7542566)   +10 more
core   +1 more source

Major adverse cardiovascular events with remote ischemic conditioning and without remote ischemic conditioning.

, 2013
Major adverse cardiovascular events with remote ischemic conditioning and without remote ischemic conditioning.
Daniel Brevoord (313448), Peter Kranke (313449), Marijn Kuijpers (313450), Benedikt Preckel (313453), Nina Weber (313451), Markus Hollmann (313452)   +5 more
core   +1 more source

Kaplan–Meier curves for stroke/SEE, all bleeding, major bleeding, intracranial hemorrhage, all-cause death, and major adverse cardiovascular or neurological event.

, 2023
Abbreviations: PAF, paroxysmal atrial fibrillation; SEE, systemic embolic events; MACNE, major adverse cardiovascular or neurological events.
Takenori Yamaguchi (9606963), Satoshi Teramukai (386488), Takeshi Yamashita (6269141), Ken Okumura (832263), Hiroyuki Tsutsui (181537), Tetsuya Kimura (54059), Hiroshi Inoue (32292), Shinya Suzuki (361361), Masaharu Akao (233558), Atsushi Hirayama (777253), Masahiro Yasaka (6269139), Takanori Ikeda (6723904), Hirotsugu Atarashi (6269138), Atsushi Takita (3904513), Yukihiro Koretsune (223277), Yoshinori Morishima (14587713), Wataru Shimizu (401865), Kazunori Toyoda (563887)   +17 more
core   +1 more source

Effect of levothyroxine on major adverse cardiovascular events in patients with hypothyroidism and cardiovascular disease

Frontiers in Endocrinology
ObjectiveThis study aimed to evaluate the effectiveness of levothyroxine, compared to non-levothyroxine treatment, in preventing adverse cardiovascular events and mortality in patients with hypothyroidism and cardiovascular disease (CVD).MethodsThis is a retrospective study utilizing medical record data from the Yinzhou Regional Health Care Database ...
Liu, Lijia, Zhang, Haiqing, Chen, Xiaowei, Liu, Zuoxiang, Zhao, Houyu, Ma, Shizhan, Zhao, Meng, Shen, Peng, Sun, Yexiang, Lin, Hongbo, Zhan, Siyan, Zhao, Jiajun, Sun, Feng   +12 more
openaire   +2 more sources

Patient safety : Cardio and cerebrovascular risk of major adverse events following exposure to potentially inappropriate medications

, 2022
Chapter 1 introduces what is known about the current challenges of medication management in the elderly, with a special focus on management of potentially inappropriate medications (PIMs) in clinical practice.
Aguiar, João Pedro
core   +1 more source

Impact of planned concomitant coronary artery bypass grafting on risk of major adverse cardiovascular events in elective aortic hemiarch surgery

Journal of Cardiothoracic Surgery
Background Hemiarch replacement of the ascending aorta has become routine in many aortic centers. While the addition of coronary bypass does not add a lot of time to the procedure, it carries with more significant comorbidities.
Bo Chang Brian Wu, Adam M. Carroll, Nicolas Chanes, Drake S. Rosenberg, Michael J. Kirsch, Muhammad Aftab, T. Brett Reece   +6 more
doaj   +1 more source

Prognostic Impact of Interleukin-27 in Peripheral Artery Disease

Life
Atherosclerosis is a progressive arterial disease characterized by chronic inflammation, with interleukin-27 (IL-27) implicated as both a pro- and anti-inflammatory cytokine. This prospective cohort study evaluated association of circulating IL-27 levels
Nataša Kokalj, Borut Jug
doaj   +1 more source